TRP'ing up chronic kidney disease

Source: ScienceNOW - Category: Science Authors: Tags: Medicine, Diseases perspective Source Type: news

Related Links:

Over the decades, statin therapy, which reduces serum levels of low-density lipoprotein cholesterol (LDL-c), has been proved to reduce cardiovascular events by stabilizing atherosclerotic plaques; however, the risks are still residual [1 –3]. In such situation, we should consider not only LDL-c, but also other lipid profiles, including triglyceride, remnant-like particle cholesterol (RLP-c), and high-density lipoprotein cholesterol (HDL-c).
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research
Publication date: August 2018Source: American Journal of Kidney Diseases, Volume 72, Issue 2Author(s): Andrew A. HouseHeart failure and chronic kidney disease have increasing incidence and prevalence owing in part to the aging population and increasing rates of hypertension, diabetes, and other cardiovascular and kidney disease risk factors. The presence of one condition also has a strong influence on the other, leading to greater risks for hospitalization, morbidity, and death, as well as very high health care costs. Despite the frequent coexistence of heart failure and chronic kidney disease, many of the pivotal randomiz...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
This article reviews the clinical case for a special emphasis on this transition period, reviews published literature regarding prior transitional care programs, and proposes a novel iteration of the first 30 days of dialysis care: the transitional care unit (TCU). The goal of a TCU is to improve awareness of all aspects of renal replacement therapy, including modalities, access, transplantation options, and nutritional and psychosocial aspects of the disease. This enables patients to make truly informed decisions regarding their care. The TCU model is open to all patients, including incident patients with end-stage renal ...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Publication date: August 2018Source: American Journal of Kidney Diseases, Volume 72, Issue 2Author(s): Emily A. Hu, Elizabeth Selvin, Morgan E. Grams, Lyn M. Steffen, Josef Coresh, Casey M. RebholzBackgroundModerate coffee consumption has been suggested to be associated with lower risk for chronic conditions such as diabetes, a major precursor to chronic kidney disease (CKD). However, the association between coffee and CKD has not been fully established.Study DesignProspective cohort study.Setting &Participants14,209 participants aged 45 to 64 years from the Atherosclerosis Risk in Communities (ARIC) Study.Predict...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
ConclusionsA team-based safety-net primary care CKD registry did not improve BP parameters, but led to greater albuminuria quantification and more ACE inhibitor/ARB prescriptions after 1 year. Adoption of team-based CKD registries may represent an important step in translating evidence into practice for CKD management.Graphical Abstract
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Publication date: Available online 20 July 2018Source: American Journal of Kidney DiseasesAuthor(s): Daniel E. Weiner, Meyeon Park, Hocine Tighiouart, Alin A. Joseph, Myra A. Carpenter, Nitender Goyal, Andrew A. House, Chi-yuan Hsu, Joachim H. Ix, Paul F. Jacques, Clifton E. Kew, S. Joseph Kim, John W. Kusek, Todd E. Pesavento, Marc A. Pfeffer, Stephen R. Smith, Matthew R. Weir, Andrew S. Levey, Andrew G. BostomRationale &ObjectiveCardiovascular disease (CVD) is common and overall graft survival is suboptimal among kidney transplant recipients. Although albuminuria is a known risk factor for adverse outcomes among pers...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
ConclusionsAmong incident patients with ESRD with diabetes, a dose-dependent relationship between frequency of pre-ESRD hypoglycemia-related hospitalizations and post-ESRD mortality was observed. Further study of diabetic management strategies that prevent hypoglycemia as patients with chronic kidney disease transition to ESRD are warranted.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Publication date: August 2018Source: American Journal of Kidney Diseases, Volume 72, Issue 2Author(s): Perry Formanek, Elizabeth Salisbury-Afshar, Majid AfsharAmong the many adverse effects of tobacco exposure is the increased risk for progression of kidney disease. Individuals with chronic kidney disease (CKD), who already face increased cardiovascular event rates compared to the general population, are at even greater risk if they smoke. Despite these risks and the increased focus on smoking cessation in the general population in recent years, national guidelines have not specifically targeted individuals with CKD. There...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
PiT-2, a type III sodium-dependent phosphate transporter, is a causative gene for the brain arteriolar calcification in people with familial basal ganglion calcification. Here we examined the effect of PiT-2 haploinsufficiency on vascular calcification in uremic mice using wild-type and global PiT-2 heterozygous knockout mice. PiT-2 haploinsufficiency enhanced the development of vascular calcification in mice with chronic kidney disease fed a high-phosphate diet. No differences were observed in the serum mineral biomarkers and kidney function between the wild-type and PiT-2 heterozygous knockout groups.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Basic Research Source Type: research
AbstractPatiromer (Veltassa®) for oral suspension is a non-absorbed, sodium-free potassium binding polymer that exchanges calcium for potassium in the gastrointestinal (GI) tract, thereby increasing faecal potassium excretion and reducing serum potassium levels. Patiromer was approved in the USA in 2015 and is now approved in several other countries, including those of the EU, for the treatment of hyperkalaemia in adults. In clinical trials, patiromer reduced serum potassium levels and the risk of recurrent hyperkalaemia in patients with chronic kidney disease (CKD) and/or diabetic nephropathy with or without heart fai...
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Chronic Kidney Disease | Urology & Nephrology